How COVID mRNA vaccines train immune cells to make strong, lasting antibodies
Regulation of germinal center responses by SARS-CoV-2 messenger RNA vaccines
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11294177
This work looks at how COVID-19 mRNA vaccines help the body make long-lived, high-quality antibody-producing cells in mice and people.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11294177 on ClinicalTrials.gov |
What this research studies
From my point of view as a participant, researchers will compare immune responses after mRNA vaccination in both mice and people to see how antibody-making B cells form and persist. They will take blood samples and, in some cases, outpatient lymph node samples to track antibody levels, B cell types, and helper T cells over time. The team will also identify which antigen-presenting cells and sensing pathways help drive those helper T cells that support strong antibody responses. Lab tests will measure antibody strength, cell types, and molecular signals to understand why some responses last longer than others.
Who could benefit from this research
Good fit: Ideal candidates are adults who received or will receive a COVID-19 mRNA vaccine and are willing to provide blood and possibly short outpatient lymph node samples over time.
Not a fit: People who have never had an mRNA COVID vaccine or who cannot provide blood or clinic samples are unlikely to directly benefit from participating.
Why it matters
Potential benefit: If successful, this work could help improve vaccine or booster designs and timing to give people longer-lasting protection against COVID-19.
How similar studies have performed: Previous animal and early human studies show mRNA vaccines drive strong germinal center and antibody responses, but durability and the exact cellular mechanisms are still not fully known.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOCCI, MICHELA — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: LOCCI, MICHELA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.